[The effect of oral alpha-lipoic acid in overweight/obese individuals on brachial-ankle pulse wave velocity and supine blood pressure: a randomized, crossover, double-blind, placebo-controlled trial].

Yong di Huang, Nong Li, Wei guo Zhang, Xiao juan Hu, Qian Wang, Chen chen Wang, Rui wei Xu, Kai Yan, Xue yan Hou, Naerkeze, Xiaoling Wang, Wei li Yan

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

To investigate the effect of oral alpha-lipoic acid (ALA) supplement on brachial-ankle pulse wave velocity (baPWV), supine systolic blood pressure (SBP) and diastolic blood pressure (DBP) in overweight/obese individuals. An 8-week double-blind, randomized, placebo-controlled and cross-over trial with a 4-week washout between cross-over periods. Sixty-three males and 40 females aged 22 - 57 years old who met the inclusion criteria as (1) Han ethnicity; (2) 20 - 60 years old; (3) BMI ≥ 25 kg/m(2) and having at least one of the following risk factors: borderline hypertension (130 mm Hg ≤ SBP < 140 mm Hg and/or 85 mm Hg ≤ supine DBP< 90 mm Hg), dyslipidemia (fasting total cholesterol ≥ 5.2 mmol/L or HDL-C < 1.04 mmol/L), or impaired fasting glucose (6.1 mmol/L ≤ fasting glucose < 7.0 mmol/L); (4) Not on any antioxidant vitamin supplement. They were randomly assigned to Group 1 or Group 2 in a 1:1 ratio balanced for gender. Group 1 received 8 weeks ALA (1200 mg/day) followed by 4-week washout period and followed by another 8 weeks placebo; while Group 2 received 8 weeks placebo (1200 mg/day) followed by 4-week washout period, and followed by ALA treatment for 8 weeks. BaPWV and supine blood pressure were measured at the beginning of 1(st) phase and 2(nd) phase and at the endpoint of the whole trial. Mixed effect linear regression model was performed to compare the change of baPWV and supine blood pressure between ALA group and placebo group. BaPWV decreased -33.03 cm/s ± 130.70 cm/s for ALA group and increased 5.66 cm/s ± 139.89 cm/s for placebo group, supine systolic blood pressure decreased -4.09 mm Hg ± 9.18 mm Hg for ALA group and -2.32 mm Hg ± 8.16 mm Hg for placebo group. Supine diastolic blood pressure decreased -1.29 mm Hg ± 6.55 mm Hg for ALA group and -0.48 mm Hg ± 6.63 mm Hg for placebo group. These three mix-effect models did not show significant effect of ALA treatment after adjustment on baseline values, sex, age, treatment sequence or period. The current trial did not provide evidence that oral intake of ALA for 8 weeks had significant effects on lowering baPWV, supine systolic blood pressure or supine diastolic blood pressure.

Original languageEnglish (US)
Pages (from-to)290-296
Number of pages7
JournalZhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi
Volume32
Issue number3
StatePublished - Jan 1 2011
Externally publishedYes

Fingerprint

Thioctic Acid
Pulse Wave Analysis
Ankle
Arm
Placebos
Blood Pressure
Fasting
Linear Models
Social Adjustment
Glucose

ASJC Scopus subject areas

  • Medicine(all)

Cite this

[The effect of oral alpha-lipoic acid in overweight/obese individuals on brachial-ankle pulse wave velocity and supine blood pressure : a randomized, crossover, double-blind, placebo-controlled trial]. / Huang, Yong di; Li, Nong; Zhang, Wei guo; Hu, Xiao juan; Wang, Qian; Wang, Chen chen; Xu, Rui wei; Yan, Kai; Hou, Xue yan; Naerkeze, ; Wang, Xiaoling; Yan, Wei li.

In: Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi, Vol. 32, No. 3, 01.01.2011, p. 290-296.

Research output: Contribution to journalArticle

Huang, Yong di ; Li, Nong ; Zhang, Wei guo ; Hu, Xiao juan ; Wang, Qian ; Wang, Chen chen ; Xu, Rui wei ; Yan, Kai ; Hou, Xue yan ; Naerkeze, ; Wang, Xiaoling ; Yan, Wei li. / [The effect of oral alpha-lipoic acid in overweight/obese individuals on brachial-ankle pulse wave velocity and supine blood pressure : a randomized, crossover, double-blind, placebo-controlled trial]. In: Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi. 2011 ; Vol. 32, No. 3. pp. 290-296.
@article{070130e1da7f49669fd9392074995f6b,
title = "[The effect of oral alpha-lipoic acid in overweight/obese individuals on brachial-ankle pulse wave velocity and supine blood pressure: a randomized, crossover, double-blind, placebo-controlled trial].",
abstract = "To investigate the effect of oral alpha-lipoic acid (ALA) supplement on brachial-ankle pulse wave velocity (baPWV), supine systolic blood pressure (SBP) and diastolic blood pressure (DBP) in overweight/obese individuals. An 8-week double-blind, randomized, placebo-controlled and cross-over trial with a 4-week washout between cross-over periods. Sixty-three males and 40 females aged 22 - 57 years old who met the inclusion criteria as (1) Han ethnicity; (2) 20 - 60 years old; (3) BMI ≥ 25 kg/m(2) and having at least one of the following risk factors: borderline hypertension (130 mm Hg ≤ SBP < 140 mm Hg and/or 85 mm Hg ≤ supine DBP< 90 mm Hg), dyslipidemia (fasting total cholesterol ≥ 5.2 mmol/L or HDL-C < 1.04 mmol/L), or impaired fasting glucose (6.1 mmol/L ≤ fasting glucose < 7.0 mmol/L); (4) Not on any antioxidant vitamin supplement. They were randomly assigned to Group 1 or Group 2 in a 1:1 ratio balanced for gender. Group 1 received 8 weeks ALA (1200 mg/day) followed by 4-week washout period and followed by another 8 weeks placebo; while Group 2 received 8 weeks placebo (1200 mg/day) followed by 4-week washout period, and followed by ALA treatment for 8 weeks. BaPWV and supine blood pressure were measured at the beginning of 1(st) phase and 2(nd) phase and at the endpoint of the whole trial. Mixed effect linear regression model was performed to compare the change of baPWV and supine blood pressure between ALA group and placebo group. BaPWV decreased -33.03 cm/s ± 130.70 cm/s for ALA group and increased 5.66 cm/s ± 139.89 cm/s for placebo group, supine systolic blood pressure decreased -4.09 mm Hg ± 9.18 mm Hg for ALA group and -2.32 mm Hg ± 8.16 mm Hg for placebo group. Supine diastolic blood pressure decreased -1.29 mm Hg ± 6.55 mm Hg for ALA group and -0.48 mm Hg ± 6.63 mm Hg for placebo group. These three mix-effect models did not show significant effect of ALA treatment after adjustment on baseline values, sex, age, treatment sequence or period. The current trial did not provide evidence that oral intake of ALA for 8 weeks had significant effects on lowering baPWV, supine systolic blood pressure or supine diastolic blood pressure.",
author = "Huang, {Yong di} and Nong Li and Zhang, {Wei guo} and Hu, {Xiao juan} and Qian Wang and Wang, {Chen chen} and Xu, {Rui wei} and Kai Yan and Hou, {Xue yan} and Naerkeze and Xiaoling Wang and Yan, {Wei li}",
year = "2011",
month = "1",
day = "1",
language = "English (US)",
volume = "32",
pages = "290--296",
journal = "Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi",
issn = "0254-6450",
publisher = "Zhonghua Yixuehui Zazhishe",
number = "3",

}

TY - JOUR

T1 - [The effect of oral alpha-lipoic acid in overweight/obese individuals on brachial-ankle pulse wave velocity and supine blood pressure

T2 - a randomized, crossover, double-blind, placebo-controlled trial].

AU - Huang, Yong di

AU - Li, Nong

AU - Zhang, Wei guo

AU - Hu, Xiao juan

AU - Wang, Qian

AU - Wang, Chen chen

AU - Xu, Rui wei

AU - Yan, Kai

AU - Hou, Xue yan

AU - Naerkeze,

AU - Wang, Xiaoling

AU - Yan, Wei li

PY - 2011/1/1

Y1 - 2011/1/1

N2 - To investigate the effect of oral alpha-lipoic acid (ALA) supplement on brachial-ankle pulse wave velocity (baPWV), supine systolic blood pressure (SBP) and diastolic blood pressure (DBP) in overweight/obese individuals. An 8-week double-blind, randomized, placebo-controlled and cross-over trial with a 4-week washout between cross-over periods. Sixty-three males and 40 females aged 22 - 57 years old who met the inclusion criteria as (1) Han ethnicity; (2) 20 - 60 years old; (3) BMI ≥ 25 kg/m(2) and having at least one of the following risk factors: borderline hypertension (130 mm Hg ≤ SBP < 140 mm Hg and/or 85 mm Hg ≤ supine DBP< 90 mm Hg), dyslipidemia (fasting total cholesterol ≥ 5.2 mmol/L or HDL-C < 1.04 mmol/L), or impaired fasting glucose (6.1 mmol/L ≤ fasting glucose < 7.0 mmol/L); (4) Not on any antioxidant vitamin supplement. They were randomly assigned to Group 1 or Group 2 in a 1:1 ratio balanced for gender. Group 1 received 8 weeks ALA (1200 mg/day) followed by 4-week washout period and followed by another 8 weeks placebo; while Group 2 received 8 weeks placebo (1200 mg/day) followed by 4-week washout period, and followed by ALA treatment for 8 weeks. BaPWV and supine blood pressure were measured at the beginning of 1(st) phase and 2(nd) phase and at the endpoint of the whole trial. Mixed effect linear regression model was performed to compare the change of baPWV and supine blood pressure between ALA group and placebo group. BaPWV decreased -33.03 cm/s ± 130.70 cm/s for ALA group and increased 5.66 cm/s ± 139.89 cm/s for placebo group, supine systolic blood pressure decreased -4.09 mm Hg ± 9.18 mm Hg for ALA group and -2.32 mm Hg ± 8.16 mm Hg for placebo group. Supine diastolic blood pressure decreased -1.29 mm Hg ± 6.55 mm Hg for ALA group and -0.48 mm Hg ± 6.63 mm Hg for placebo group. These three mix-effect models did not show significant effect of ALA treatment after adjustment on baseline values, sex, age, treatment sequence or period. The current trial did not provide evidence that oral intake of ALA for 8 weeks had significant effects on lowering baPWV, supine systolic blood pressure or supine diastolic blood pressure.

AB - To investigate the effect of oral alpha-lipoic acid (ALA) supplement on brachial-ankle pulse wave velocity (baPWV), supine systolic blood pressure (SBP) and diastolic blood pressure (DBP) in overweight/obese individuals. An 8-week double-blind, randomized, placebo-controlled and cross-over trial with a 4-week washout between cross-over periods. Sixty-three males and 40 females aged 22 - 57 years old who met the inclusion criteria as (1) Han ethnicity; (2) 20 - 60 years old; (3) BMI ≥ 25 kg/m(2) and having at least one of the following risk factors: borderline hypertension (130 mm Hg ≤ SBP < 140 mm Hg and/or 85 mm Hg ≤ supine DBP< 90 mm Hg), dyslipidemia (fasting total cholesterol ≥ 5.2 mmol/L or HDL-C < 1.04 mmol/L), or impaired fasting glucose (6.1 mmol/L ≤ fasting glucose < 7.0 mmol/L); (4) Not on any antioxidant vitamin supplement. They were randomly assigned to Group 1 or Group 2 in a 1:1 ratio balanced for gender. Group 1 received 8 weeks ALA (1200 mg/day) followed by 4-week washout period and followed by another 8 weeks placebo; while Group 2 received 8 weeks placebo (1200 mg/day) followed by 4-week washout period, and followed by ALA treatment for 8 weeks. BaPWV and supine blood pressure were measured at the beginning of 1(st) phase and 2(nd) phase and at the endpoint of the whole trial. Mixed effect linear regression model was performed to compare the change of baPWV and supine blood pressure between ALA group and placebo group. BaPWV decreased -33.03 cm/s ± 130.70 cm/s for ALA group and increased 5.66 cm/s ± 139.89 cm/s for placebo group, supine systolic blood pressure decreased -4.09 mm Hg ± 9.18 mm Hg for ALA group and -2.32 mm Hg ± 8.16 mm Hg for placebo group. Supine diastolic blood pressure decreased -1.29 mm Hg ± 6.55 mm Hg for ALA group and -0.48 mm Hg ± 6.63 mm Hg for placebo group. These three mix-effect models did not show significant effect of ALA treatment after adjustment on baseline values, sex, age, treatment sequence or period. The current trial did not provide evidence that oral intake of ALA for 8 weeks had significant effects on lowering baPWV, supine systolic blood pressure or supine diastolic blood pressure.

UR - http://www.scopus.com/inward/record.url?scp=84874639708&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874639708&partnerID=8YFLogxK

M3 - Article

C2 - 21457668

AN - SCOPUS:84874639708

VL - 32

SP - 290

EP - 296

JO - Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi

JF - Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi

SN - 0254-6450

IS - 3

ER -